ALEXANDER KHARLAMOV
Founder, C.E.O., and Independent Researcher
M.D., FESC, FACC, FEACVI
De Haar Research Task Force | Foundation (DHRF)
Rotterdam - Amsterdam, The Netherlands | Tallinn, Estonia
Fostering High-Quality Honest & Fair Research Perfectionism
DHRF pioneers and develops the advanced cardiovascular service and imaging, innovative medical devices which are based on artificial intelligence, biomedical engineering, and nanomedicine nourishing research and progress
Our mission is to inspire and drive the breaking ground research in cardiovascular clinical practice taking the lead in translational and clinical studies, managing expert-level cardiovascular imaging service, contributing to the development of the novel imaging tools (professional artificial intelligence and machine learning-based cardiovascular imaging software), medical devices, promising biomedical engineering and nanotechnology solutions, national and international professional standards of health care in general and interventional cardiology, cardiovascular imaging, disseminating the knowledge to the scientific professional community and the general public, supporting the highest standards of quality and safety in both imaging and therapy in order to pave the way toward the dramatic reduction of cardiovascular burden across the globe rescuing millions of lives.
Advanced Cardiovascular Imaging in Non-Invasive and Interventional Cardiology; Bioresorbable Scaffolds (with Sensors and Nanoparticles)
Cardiovascular Health and Sex Characteristics, Sexual Orientation and Gender Identity
Artificial Womb (Ectogenesis), Same-Sex Gametes In Vitro Fertilization (Degendered Reproduction) and Transhumanism
(Hi-Tech for Reproductive Freedom)
Artificial Intelligence and Public Health in Cardiology
Consciousness and Theory of Everything; Immortality in Singularity; Philosophy of Science
The idea of DHRF was born in Rotterdam on February 15th, 2013. The DHRF develops and supports innovations in interventional cardiology, medical device development, intracoronary/ intravascular (QCA, IVUS, OCT, NIRS, photoacoustic), and non-invasive imaging (CCTA, CMR, MPI, PET, TTE), including artificial intelligence/ machine learning-based technologies, biomedical engineering, neurophysiology (primarily, consciousness), and nanomedicine (multifunctional nanoparticles for theranostics of atherosclerosis). The DHRF provides start-ups and small enterprises in the Netherlands, Estonia, the United States, and countries of the Commonwealth of Nations with the relevant research service and assistance in representing, promoting, and supporting their biomedical business in Europe, as well as the relevant translational and clinical studies including CE mark procedures. The DHRF is an SME business located in Tallinn (Estonia) and Rotterdam - Amsterdam (the Netherlands) with ambitions of further development and expansion inside the Lowlands, Europe, and the United States. We do not collaborate with Russian institutions.
